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The level of caveolin-1 expression closely correlates
with the oncogenic transformation of NIH 3T3 cells, the
proliferation of human cancer cells, and the differenti-
ation of adipocytes and muscle cells. However, the role
of caveolin-1 in endothelial cell proliferation and differ-
entiation remains unknown. Here, we have shown that
angiogenic growth factors that stimulate endothelial
cell proliferation lead to dramatic reductions in caveo-
lin-1 expression. In addition, using an in vitro Matrigel
assay system, we studied the potential role of caveolin-1
in capillary-like tubule formation (i.e. endothelial cell
differentiation) using human microvascular endothelial
cells (HMEC-1). We showed that the level of endogenous
caveolin-1 expression increased in a time-dependent
manner when endothelial cells underwent differentia-
tion and that the maximum level of caveolin-1 expres-
sion occurred just prior to the formation of capillary-
like tubules. Interestingly, overexpression of caveolin-1,
via an adenoviral gene delivery system, clearly acceler-
ated endothelial cell differentiation/tubule formation
and led to a dramatic 3-fold increase in the number of
capillary-like tubular structures. Conversely, down-reg-
ulation of caveolin-1 expression, via an antisense adeno-
viral approach, reduced the number of capillary-like
tubules formed by >10-fold. Consistent with the unique
function of caveolin-1 in interacting with key signaling
molecules, delivery of the caveolin-1 scaffolding domain
into the cytoplasm of living endothelial cells was also
sufficient to enhance capillary-like tubule formation.
Taken together, these results clearly demonstrate that
caveolin-1 and the caveolin-1 scaffolding domain play an
important positive role in the regulation of endothelial
cell differentiation, a prerequisite step in the process of
angiogenesis.
In the adult, endothelial cells normally remain quiescent,
show a low turnover rate, and rarely proliferate (1). But once
they receive an appropriate stimulus, endothelial cells rapidly
proliferate and form new blood vessels by a process called
angiogenesis. How do endothelial cells determine whether to
remain quiescent or to become proliferative? In this regard, our
greatest insights into the regulation of the angiogenic process
are derived from the study of embryonic development and
tumorigenesis. Several growth factors responsible for endothe-
lial cell growth and differentiation have been identified and
characterized. These activators include vascular endothelial
growth factor (VEGF),1 also termed vascular permeability fac-
tor (2–4); placenta growth factor (5); platelet-derived growth
factor (PDGF) (6); fibroblast growth factor (7); and hepatocyte
growth factor (HGF), also termed scatter factor (8).
In addition to these activators, negative regulators of angio-
genesis are also involved in controlling the formation of new
blood vessels (9). These include angiostatin (10), endostatin
(11), transforming growth factor- (12), thrombospondin-1 (13),
fumagillin (14), 2-methoxyestradiol (15), and thalidomide (16).
These inhibitors block angiogenic activator-induced endothe-
lial cell migration, proliferation, and blood vessel formation
(11, 17). Although a variety of angiogenesis activators and
inhibitors have been identified and characterized, there is very
little information on the mechanisms by which angiogenesis
activators and inhibitors regulate the state of endothelial cells.
Recently, we demonstrated that angiogenesis activators and
inhibitors reciprocally regulate caveolin-1 expression and
caveolae formation (18). Overexpression of caveolin-1 inhibits
the VEGF receptor (Flk-1)-mediated mitogenic signaling cas-
cade, suggesting that caveolin-1 might be a cellular target for
angiogenesis regulators.
Three mammalian caveolin genes encoding four proteins
have been identified and characterized (19). These include
caveolin-1, caveolin-2, and caveolin-3. Caveolin-1 and caveo-
lin-1 are derived via alternative initiation during translation
(20). Caveolin-1 and caveolin-2 are coexpressed and form a
hetero-oligomeric complex (21) in many cell types, with partic-
ularly high levels in adipocytes, endothelia, epithelia, and fi-
broblasts, whereas caveolin-3 expression is muscle-specific (22,
23). A large body of evidence supports the idea that caveolins
interacts with a number of signaling molecules, including re-
ceptor and non-receptor tyrosine kinases (epidermal growth
factor, Neu, and Src family tyrosine kinases), protein kinase C,
heterotrimeric G-protein -subunits, and endothelial nitric-
oxide synthase (24). Domain mapping studies revealed that
interaction of caveolins with these signaling molecules is me-
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diated by a membrane-proximal region of the caveolins termed
the caveolin scaffolding domain (residues 82–101 in caveolin-
1). The caveolin scaffolding domain recognizes a specific caveo-
lin-binding motif (i.e. consisting of closely spaced aromatic
amino acids) located within the catalytic domain of a given
signaling molecule (24, 25). In general, interaction with caveo-
lins or the caveolin scaffolding domain inhibits the activity of
caveolin-binding signaling molecules.
Although expressed in many cell types, caveolin-1 is down-
regulated or absent in oncogene (v-abl, bcr-abl, Ha-ras)-trans-
formed NIH 3T3 cells (26) as well as in human cancer cells (27,
28). Overexpression of caveolin-1 in Ha-ras- and v-abl-trans-
formed NIH 3T3 cells abrogates their anchorage-independent
growth by directly inhibiting the Ras-MAPK (p42/44) signaling
cascade (29). Similarly, overexpression of caveolin-1 in human
breast cancer cells (possessing no detectable caveolin-1) inhib-
its cell proliferation and colony formation (27). Conversely,
targeted down-regulation of caveolin-1 by the expression of
antisense caveolin-1 is sufficient to induce cell transformation
and tumor formation apparently by the activation of MAPK
(ERK1/2) (30). Furthermore, caveolin-1 expression is down-
regulated in rapidly dividing cells and dramatically up-regu-
lated in confluent cells (30). These results suggest that caveolin
may function as a transformation suppressor gene (19). Re-
cently, we demonstrated that caveolin-3 expression is elevated
during the differentiation of C2C12 skeletal myoblasts (31),
and this differentiation process is prevented by down-regula-
tion of caveolin-3 expression. Consistent with a role for caveo-
lin-1 in cell differentiation, Gumbleton and co-workers (32)
observed up-regulation of caveolin-1 expression with concomi-
tant formation of caveolae as alveolar epithelial type II lung
cells trans-differentiate into alveolar epithelial type I cells.
These results imply a potential role for caveolins in cellular
differentiation.
Angiogenesis is a complex process that involves a series of
discrete stages or phases, including (i) an initial proliferative
phase and (ii) a terminal differentiation phase. In this work, we
show that caveolin-1 is down-regulated by endothelial growth
factors that stimulate the initial proliferative phase; this is
consistent with previous evidence demonstrating that caveo-
lin-1 is a negative regulator of cell proliferation and cell cycle
progression. Conversely, we evaluated the effect of caveolin-1
expression on endothelial cell differentiation. This was exper-
imentally achieved by plating the endothelial cells at conflu-
ency to avoid the known negative effects of caveolin-1 on cell
proliferation. Under these conditions of complete confluency,
we show that caveolin-1 expression stimulates endothelial cell
differentiation and tubule formation. This is also consistent
with the previous observations that caveolin-1 and caveolin-3
are most highly expressed in terminally differentiated cell
types and that caveolin gene expression is up-regulated during
a variety of differentiation processes. Consistent with this in-
terpretation, we also show that caveolin-1 levels are normally
transiently up-regulated during the endothelial cell differenti-
ation process. Thus, caveolin-1 expression is down-regulated
during the proliferative phase and up-regulated during the
differentiation phase of angiogenesis. Furthermore, our cur-
rent findings are the first demonstration that caveolin-1 ex-
pression can stimulate a differentiation process. Similarly, we
have shown previously that caveolin-1 can reverse the onco-
genic behavior of transformed NIH 3T3 fibroblasts in culture
(29).
EXPERIMENTAL PROCEDURES
Materials—A monoclonal antibody directed against caveolin-1 (clone
2297, recognizing residues 61–71) (20) was kindly provided by Dr.
Roberto Campos-Gonzalez (BD-Transduction Laboratories, Lexington,
KY). Reagents and other supplies were obtained from the following
commercial sources. VEGF, PDGF, and basic fibroblast growth factor
were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY).
HGF and a monoclonal antibody directed against -actin were pur-
chased from Sigma. Antibodies against PECAM-1, VEGF receptor-2
(Flk-1), GFP, and c-Myc were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Rhodamine-conjugated streptavidin was ob-
tained from Jackson ImmunoResearch Laboratories, Inc. (West Grove,
PA). The angiogenesis assay kit was purchased from Chemicon Inter-
national, Inc. (Temecula, CA). Penetratin-caveolin-1 peptides were syn-
thesized by the NIH-designated Peptide Core Facility of Tufts Medical
School (Boston, MA). The ProLong Anti-fade reagent was purchased
from Molecular Probes, Inc. (Eugene, OR). The BCA protein assay kit
was purchased from Pierce.
Cell Culture and Growth Factor Treatment—Bovine aortic endothe-
lial cells (BAECs) were grown in Dulbecco’s modified Eagle’s medium
with 10% heat-inactivated fetal bovine serum (normal growth medium).
Human microvascular endothelial cells (HMEC-1) were grown in
MCDB 131 with 10% heat-inactivated fetal bovine serum (normal
growth medium), as described previously (33). Western blot analysis
using antibodies against PECAM-1 and VEGF receptor-2 (Flk-1) con-
firmed the endothelial origin of HMEC-1 cells.2 To study the effect of
growth factors on caveolin-1 expression, BAECs (1  104 cells/well) or
HMEC-1 cells (2  104 cells/well) were treated with VEGF, PDGF, or
HGF in medium containing 0.5% fetal bovine serum for 24 h. After
treatment, the cells were washed with phosphate-buffered saline, lysed,
and prepared for Western blot analysis as described below.
Infection of HMEC-1 Cells with an Adenoviral Vector Containing
Either Sense or Antisense Caveolin-1—The construction of recombinant
Myc epitope-tagged caveolin-1 adenovirus (Ad-Cav-1), green fluorescent
protein adenovirus (Ad-GFP), and tetracycline transactivator adenovi-
rus (Ad-tTA) were as we described previously (34). This adenoviral
vector system is inducible and requires a coactivator for expression
(Ad-tTA) as previously described (34). The adenovirus harboring anti-
sense caveolin-1 (Ad-Cav-1-AS) is not inducible and was constructed
and characterized as we previously described (35). HMEC-1 cells were
seeded at a density of 8  104 cells/ml in six-well plates and co-
incubated with Ad-Cav-1 and Ad-tTA in serum-free medium for 1 h,
followed by incubation in growth medium for 24 h. The level of caveo-
lin-1 expression was assessed by Western blot analysis using a specific
monoclonal antibody directed against either caveolin-1 or the c-Myc
epitope tag. A combination of various titers of Ad-Cav-1 and Ad-tTA was
employed to achieve optimum levels of caveolin-1 expression. The effi-
ciency of the infection was determined by immunofluorescent staining
with antibodies against caveolin-1. As a control, HMEC-1 cells were
co-infected with Ad-GFP and Ad-tTA or infected with Ad-Cav-1 alone.
For antisense caveolin-1 studies, HMEC-1 cells seeded at a density of
8  104 cells/ml in six-well plates were incubated with Ad-Cav-1-AS in
serum-free medium for 1 h, followed by incubation in growth medium
for 24 h. The level of caveolin-1 down-regulation was assessed by
Western blot analysis using a specific monoclonal antibody directed
against caveolin-1.
Capillary-like Tubule Formation Assay—The formation of capillary-
like tubular structures was assessed in Matrigel-coated multiwell
plates essentially as described previously (36). HMEC-1 cells were
infected with or without adenovirus harboring sense or antisense caveo-
lin-1 for 24 h as described above. Cells were then seeded at a density of
30  104 cells/ml in growth medium in Matrigel-coated multiwell plates
and incubated at 37 °C for a period of 0–24 h. To study the effect of
caveolin-1 peptides on tubule formation, HMEC-1 cells (30  104 cells/
ml) were incubated in Matrigel-coated multiwell plates at 37 °C for 1 h
to allow cells to attach to the Matrigel, followed by treatment with
penetratin-caveolin-1 fusion peptides (5 M) for 20 h. The formation of
tubular structures was examined using an Olympus IX70 microscope.
Immunoblot Analysis—The expression levels of caveolin-1 were de-
termined by Western blot analysis. Briefly, cells were washed with
phosphate-buffered saline and solubilized with lysis buffer containing
10 mM Tris-HCl (pH 8.0), 150 mM sodium chloride, 1% Triton X-100, 60
mM octyl glucoside, and protease inhibitors. Total cellular proteins were
separated by SDS-PAGE and electrotransferred to nitrocellulose mem-
branes for immunoblotting using enhanced chemiluminescence. Prior
to loading, the protein concentration of the samples was measured by
the BCA method using bovine serum albumin as the standard.
Internalization of Penetratin-Caveolin Scaffolding Domain Peptides
by HMEC-1 Cells—After incubation with biotin-penetratin (B-Pen) or
2 J. Liu, X. Wang, D. S. Park, and M. P. Lisanti, unpublished data.
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biotin-penetratin-caveolin-1 scaffolding domain (B-Pen-C1-SD) fusion
peptides (at a concentration of 2 M) in growth medium at 37 °C for 2 h,
HMEC-1 cells were washed with phosphate-buffered saline and fixed
with 3% paraformaldehyde. After fixation, cells were permeabilized
with 0.1% Triton X-100 in phosphate-buffered saline containing 0.2%
bovine serum albumin. Internalized peptides were visualized by incu-
bation of the cells with rhodamine-conjugated streptavidin in the per-
meabilization buffer. The internalized peptides were visualized using
the Olympus IX70 fluorescent microscope equipped with a photometric
CCD camera under the rhodamine channel.
RESULTS
Angiogenic Growth Factors Down-regulate Caveolin-1 Ex-
pression in Subconfluent Endothelial Cells—We have previ-
ously shown that angiogenic growth factors down-regulate
caveolin-1 expression in ECV 304 cells (18), suggesting that
caveolin-1 may be important in angiogenesis. After publication
of our results, the endothelial origin of ECV 304 cells was
recently questioned (37). To re-evaluate the possible effects of
angiogenic factors on caveolin-1 expression in endothelial cells,
we next treated primary BAECs and a well established human
endothelial cell line (HMEC-1) (33) with a panel of different
angiogenic growth factors such as VEGF, PDGF, and HGF and
examined the level of caveolin-1 expression in these cells.
Fig. 1A shows that treatment of BAECs with either VEGF or
PDGF at a concentration of 10 ng/ml for 24 h dramatically
down-regulated caveolin-1 expression. Similarly, treatment of
rat capillary endothelial cells with an angiogenic factor (basic
fibroblast growth factor) led to down-regulation of caveolin-1
expression (data not shown). Furthermore, treatment of
HMEC-1 cells with VEGF, PDGF, or HGF caused the dose-de-
pendent down-regulation of caveolin-1 expression (Fig. 1B).
Our current results are consistent with our previous observa-
tions, indicating that caveolin-1 may be a bona fide cellular
target for angiogenesis regulators in endothelial cells. Impor-
tantly, however, angiogenic growth factors did not affect caveo-
lin-1 expression in confluent endothelial cells (data not shown).
Up-regulation of Caveolin-1 Expression Occurs Just Prior to
Endothelial Tubule Formation—Angiogenesis involves the mi-
gration, proliferation, and differentiation of endothelial cells.
To test the hypothesis that caveolin-1 plays an important role
in angiogenesis, we next employed an in vitro angiogenesis
assay system. To focus on the possible effects of caveolin-1 on
endothelial cell differentiation, we seeded HMEC-1 cells at
super-confluency (see “Experimental Procedures”) to minimize
the effects of caveolin-1 on cell proliferation.
We have recently shown that in nontransformed NIH 3T3
cells, caveolin-1 levels are down-regulated in rapidly dividing
cells, but dramatically increased in confluent cells; in these
confluent cells, caveolin-1 was specifically concentrated at the
areas of cell-cell contact (30, 38). These results suggest a po-
tential role for caveolin-1 in regulating contact inhibition and
perhaps cellular differentiation. Indeed, we (31) and others (32)
have demonstrated that caveolins are critical for the differen-
tiation of muscle cells as well as epithelial cells. Based on these
observations, we would predict that caveolin-1 should increase
during the process of endothelial cell differentiation/tubule
formation.
Fig. 2A shows that incubation of HMEC-1 cells on Matrigel
from 0 to 24 h caused the time-dependent formation of tubular
structures. These tubular structures first appeared after 12 h
of incubation and developed into a well organized capillary-like
network after 24 h of incubation. Interestingly, Western blot
analysis revealed that caveolin-1 levels steadily increased in a
time-dependent manner and reached their maximum after 8 h
of incubation (Fig. 2B), 4 h prior to the beginning of tubule
formation (Fig. 2A). Conversely, caveolin-1 levels then de-
creased from 12 to 24 h and returned to basal levels after 24 h
of incubation (Fig. 2B). These results suggest that a transient
increase in caveolin-1 levels may be functionally important in
the regulation of endothelial cell differentiation/tubule
formation.
Recombinant Expression of Caveolin-1 Enhances the Forma-
tion of Endothelial Tubular Structures—To better assess the
potential role of caveolin-1 in the regulation of endothelial cell
differentiation, we next transiently up-regulated or down-reg-
ulated the levels of caveolin-1 in confluent HMEC-1 cells. For
this purpose, we employed a series of well characterized adeno-
viral vectors that harbor the caveolin-1 cDNA either in the
sense or antisense orientation.
Fig. 3 shows the dose-dependent overexpression of caveolin-1
in HMEC-1 cells co-infected with Ad-Cav-1 and Ad-tTA. A
maximum level of caveolin-1 expression was obtained by infect-
ing HMEC-1 cells with both Ad-Cav-1 and Ad-tTA (200 pfu/cell
FIG. 1. Angiogenesis activators down-regulate caveolin-1 ex-
pression in endothelial cells. A, down-regulation of caveolin-1 ex-
pression in BAECs. BAECs (seeded at a density of 1  104 cells/well in
24-well plates; see “Experimental Procedures”) were treated with or
without 10 ng/ml VEGF or PDGF in Dulbecco’s modified Eagle’s me-
dium containing 0.5% fetal bovine serum for 24 h. The level of caveo-
lin-1 was determined by Western blot analysis using a specific antibody
directed against caveolin-1 (Cav-1) (upper panels). The same membrane
was reprobed with an antibody directed against -actin as a control for
equal protein loading (lower panels). B, down-regulation of caveolin-1
expression in HMEC-1 cells. Human microvascular endothelial cells
(seeded at a density of 2  104 cells/well in 24-well plates) were treated
with or without 0–100 ng/ml VEGF, PDGF, or HGF in MCDB 131
medium containing 0.5% fetal bovine serum for 24 h. The level of
caveolin-1 was determined by Western blot analysis using a specific
antibody directed against caveolin-1. The same membranes were re-
probed with a monoclonal antibody directed against -actin as a control
for equal protein loading.
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each) (Figs. 3 and 5B). Longer exposures were required to reveal
endogenous caveolin-1 expression in the HMEC-1 cells (see Fig.
5B). Importantly, there was no transduced expression of caveo-
lin-1 either in cells infected with Ad-Cav-1 alone or in cells
co-infected with Ad-GFP and Ad-tTA, although co-infection of
Ad-GFP and Ad-tTA led to GFP expression (Figs. 3 and 5B).
If caveolin-1 expression is important for the regulation of
endothelial cell differentiation, we would predict that prema-
ture up-regulation of caveolin-1 might lead to early endothelial
tubule formation. Fig. 2A shows that the formation of mature
tubules required 24 h in non-infected HMEC-1 cells. How-
ever, overexpression of caveolin-1 resulted in the initial forma-
tion of tubular structures as early as 6 h of incubation on
Matrigel (data not shown). By 12 h, caveolin-1 overexpression
resulted in the formation of 17  2.5 capillary-like tubules/well,
whereas only 5  0.9 tubules were found in non-infected cells
(Fig. 4).
After 20 h of incubation, 23  2.5 tubules/well were ob-
served in non-infected cells. In striking contrast, the tubules
increased to 62  5.5/well in caveolin-1-overexpressing cells,
representing a 2.7-fold increase in tubule formation (p 
0.001) (Fig. 5).
As a critical negative control, we also assessed the effects of
expressing an irrelevant protein, i.e. GFP. Importantly, infec-
tion of HMEC-1 cells with Ad-Cav-1 alone or co-infection with
Ad-GFP and Ad-tTA did not affect tubule formation (Fig. 5).
Down-regulation of Caveolin-1 Dramatically Inhibits Endo-
thelial Tubule Formation—Our previous results demonstrated
that down-regulation of caveolin-1 expression causes hyperac-
tivation of the p42/44 MAPK cascade and oncogenic transfor-
mation of NIH 3T3 cells (30), indicating that down-regulation
of caveolin-1 can negatively affect cell differentiation. To fur-
ther examine the effect of caveolin-1 on endothelial cell differ-
entiation, we next used an antisense approach. HMEC-1 cells
were first infected with the antisense caveolin-1 adeno-
viral vector for 1 h, followed by incubation in growth medium
for 24 h to significantly down-regulate the levels of caveolin-1
(Fig. 6, A and B). The transduced cells were then plated onto
Matrigel and incubated for an additional 24 h. In non-infected
control cells, tubular structures appeared as early as 12 h of
incubation; and after 24 h of incubation, 27  2.08 tubules/well
developed (Fig. 6). In striking contrast, cells expressing anti-
sense caveolin-1 showed few or no tubular structures even after
24 h of incubation (Fig. 6). Thus, down-regulation of caveolin-1
apparently prevents endothelial cell differentiation/tubule
formation.
Internalization of the Caveolin-1 Scaffolding Domain Peptide
Stimulates Endothelial Tubule Formation—To examine the
possible role of the caveolin-1 scaffolding domain in mediating
the ability of caveolin-1 to stimulate endothelial cell differen-
tiation, we next synthesized a panel of caveolin-1 scaffolding
domain peptides as C-terminal fusion proteins with penetratin
(Pen-C1-SD) (Fig. 7). Penetratin is a 16-amino acid peptide
that corresponds to amino acids 43–58 of the homeodomain of
antennapedia, a Drosophila transcription factor. Attachment of
penetratin to peptides or oligonucleotides allows their efficient
delivery to the cytoplasm and the nucleus of a wide variety of
living cells via a non-endocytic and non-degradative pathway
(39, 40). Because a mutant form of penetratin with three intro-
duced prolines (3Pro-penetratin) is delivered preferentially to
the cytoplasm of living cells (39), we also synthesized another
set of fusion peptides with this form of penetratin attached to
FIG. 2. Up-regulation of caveolin-1 expression occurs just
prior to endothelial tubule formation. HMEC-1 cells were seeded
at a density of 30  104 cells/ml in 24-well plates precoated with
Matrigel (as suggested by Chemicon International, Inc.) and incubated
from 0 to 24 h as shown in A. At the indicated times, cells were lysed,
and cell lysates were subjected to SDS-PAGE and Western blot analysis
using a specific antibody probe directed against caveolin-1 (Cav-1) (B).
Note that the level of caveolin-1 increased in a time-dependent manner
and reached maximum levels after 8 h of incubation (see arrow in B), a
time at which few or no capillary-like tubular structures were observed
(A). Tubules first became apparent after 12 h of incubation. In B, the
same membrane was reprobed with a monoclonal antibody directed
against -actin as a control for equal protein loading.
FIG. 3. Adenoviral vector-mediated expression of caveolin-1
and GFP in HMEC-1 cells. HMEC-1 cells were transduced with the
following three adenoviral vectors alone or in combination: Ad-Cav-1,
Ad-GFP, or Ad-tTA. Note that co-infection with Ad-tTA was required for
the expression of either caveolin-1 or GFP, as expected (see “Experi-
mental Procedures”). Twenty-four hours post-infection, the cells were
lysed and subjected to SDS-PAGE and Western blot analysis using a
specific monoclonal antibody probe directed against caveolin-1 (Cav-1),
c-Myc, or GFP. The same membrane was reprobed with a monoclonal
antibody directed against -actin as a control for equal protein loading.
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the caveolin-1 scaffolding domain (Fig. 7).
To directly visualize the uptake of the fusion peptides by en-
dothelial cells, a biotin moiety was attached to the N terminus of
these peptides. As shown in Fig. 8 (c and d), incubation of
HMEC-1 cells with the biotin-penetratin peptides (with or with-
out the attached caveolin-1 scaffolding domain) resulted in effi-
cient uptake of the peptides into the cytoplasm and nucleus.
Consistent with previous observations (39), the biotin-3Pro-pen-
etratin peptides (with or without the attached caveolin-1 scaf-
folding domain (B-3Pro-C1-SD and B-3Pro, respectively)) were
internalized and concentrated in the cytoplasm (data not shown).
As observed above, incubation of HMEC-1 cells on Matrigel
for 20 h resulted in the formation of numerous capillary-like
FIG. 4. Recombinant expression of caveolin-1 dramatically en-
hances tubule formation by HMEC-1 cells. Twenty-four hours post-
infection with Ad-Cav-1 (200 pfu/cell) and Ad-tTA (200 pfu/ml) (Ad-Cav-
1/Ad-tTA), HMEC-1 cells were seeded at a density of 3  104 cells/well
in Matrigel-precoated 96-well plates and incubated for 12 h at 37 °C. A,
bright-field views were taken using an Olympus IX70 fluorescent mi-
croscope equipped with a photometric CCD camera. Note that as com-
pared with control cells (mock-transduced; upper panel), more capillary-
like tubules developed in the cells overexpressing caveolin-1 (lower
panel). B, capillary-like tubular structures were scored by counting the
number of tubules in each well, i.e. of either control or caveolin-1-
overexpressing cells. Data are the means  S.D. from three independ-
ent experiments, each performed in duplicate.
FIG. 5. Expression of caveolin-1, but not GFP, enhances endo-
thelial tubule formation. Twenty-four hours post-infection, HMEC-1
cells were seeded at a density of 3  104 cells/well in Matrigel-precoated
96-well plates and incubated for 20 h at 37 °C. A, bright-field views of
non-infected cells (Mock; panel a), caveolin-1 (Cav-1)-overexpressing cells
(panel b), GFP-overexpressing cells (panel c), and cells infected with
Ad-Cav-1 alone (panel d) are shown after 20 h of incubation on Matrigel.
Panel a, mock transduction; panel b, Ad-Cav-1 (200 pfu/cell) plus Ad-tTA
(200 pfu/cell); panel c, Ad-GFP (200 pfu/cell) plus Ad-tTA (200 pfu/cell);
panel d, Ad-Cav-1 alone (200 pfu/cell). B, the number of capillary-like
tubules formed after 20 h was determined as described in the legend of
Fig. 4. Data are the means  S.D. from three independent experiments,
each performed in duplicate. Also, an aliquot of the cells from each group
was lysed and subjected to SDS-PAGE and Western blot analysis using a
specific antibody probe directed against caveolin-1. Note that the level of
transduced caveolin-1 expression was dramatically higher than that of
endogenous caveolin-1 expression (see arrows). Expression of GFP under
these conditions was also confirmed (data not shown; see Fig. 3). The same
membrane was reprobed with a monoclonal antibody directed against
-actin as a control for equal protein loading.
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tubular structures. Interestingly, treatment of HMEC-1 cells
with caveolin-1 scaffolding domain peptides Pen-C1-SD and
B-Pen-C1-SD (5 M) increased the number of capillary-like
tubules by 5- and 4.5-fold, respectively (Fig. 9, A, panels b
and d; and B). These results are consistent with our hypothesis
that caveolin-1 plays an important role in the regulation of
endothelial cell differentiation. Furthermore, these results sug-
gest that this action is mediated through the caveolin-1 scaf-
folding domain. Similarly, treatment of HMEC-1 cells with
B-3Pro-C1-SD (5 M) caused an 4.5-fold increase in the for-
mation of tubular structures (Fig. 9, A, panel f; and B), indi-
cating that the effect of the caveolin-1 scaffolding domain on
endothelial cell differentiation does not require translocation of
the peptide into the nucleus.
As a critical negative control for these studies, we also as-
sessed the potential activity of the penetratin moiety itself.
FIG. 6. Targeted down-regulation of caveolin-1 expression in-
hibits endothelial tubule formation. Twenty-four hours post-infec-
tion with Ad-Cav-1-AS (300 pfu/cell), HMEC-1 cells were seeded at a
density of 3  104 cells/well in Matrigel-precoated 96-well plates and
incubated for 24 h at 37 °C. A, bright-field views of non-infected cells
(Mock) or cells harboring Ad-Cav-1-AS were taken after 24 h of incu-
bation on Matrigel. B, capillary-like tubular structures were scored by
counting the number of tubules in each well. Data are the means  S.D.
from three independent experiments, each performed in duplicate. Af-
ter infection, an aliquot from either non-infected or Ad-Cav-1-AS-in-
fected cells was lysed and subjected to SDS-PAGE and Western blot
analysis using a specific antibody probe directed against caveolin-1
(Cav-1). The same membrane was reprobed with a monoclonal antibody
directed against -actin as a control for equal protein loading.
FIG. 7. Schematic representation of the penetratin-caveolin-1
fusion peptides. A, penetratin (Pen; gray bars), a 16-amino acid pep-
tide corresponding to amino acids 43–58 of the homeodomain of anten-
napedia, a Drosophila transcription factor, was fused at its C terminus
to the caveolin-1 scaffolding domain (white bars), yielding Pen-C1-SD.
3Pro-penetratin is a modified form of penetratin that is preferentially
targeted to the cytoplasm and excluded from the nucleus. To monitor
the uptake of these penetratin peptides, in some cases, we placed a
biotin moiety at their extreme N terminus. B, shown is the amino acid
sequence of the fusion peptides consisting of penetratin and the caveo-
lin-1 scaffolding domain (SD). Arrows point to the three amino acids
(Ile, Gln, and Met) that were changed to proline in 3Pro-penetratin.
FIG. 8. Uptake of the penetratin-caveolin-1 fusion peptides by
HMEC-1 cells. HMEC-1 cells were left untreated (a) or were treated
with penetratin (Pen) alone (b), B-Pen alone (c), or B-Pen-C1-SD (d) at
a concentration of 2 M for 2 h at 37 °C. After fixation and permeabi-
lization, the biotinylated peptides (B-Pen alone and B-Pen-C1-SD) were
visualized by staining with rhodamine-conjugated streptavidin. Note
that B-Pen and B-Pen-C1-SD were detected both in the cytoplasm and
the nucleus of most cells. Negative controls shown in a and b did not
reveal any staining, as expected.
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Importantly, all the penetratin-only peptides used (penetratin,
B-Pen, or B-3Pro) (5 M) showed no activity in this assay
system (Fig. 9, A, panels a, c, and e; and B).
DISCUSSION
Angiogenesis is the process by which new vasculature is
derived from pre-existing blood vessels (41–43). The tight reg-
ulation of this process is mediated through a complex interplay
between the endothelial cell and the surrounding matrix. Some
of the mediators regulating this process, such as VEGF and
fibroblast growth factor, act through their cognate receptors on
endothelial cells to activate signaling pathways that include
Ras, phosphatidylinositol 3-kinase, protein kinase C, and c-Src.
The endothelial cell responds by secreting proteases and plas-
minogen activators, resulting in basement membrane degrada-
tion, followed by migration into the surrounding matrix, pro-
liferation, and, ultimately, differentiation. However, how these
familiar signaling pathways produce this wide variety of effects
in endothelial cells remains a mystery. Therefore, the search
for downstream effectors and how they translate signaling
pathways into a proliferative response versus a differentiation
response are critical. We present evidence that caveolin-1 is a
major downstream effector in endothelial cell development that
is down-regulated during cell proliferation, but when up-regu-
lated, is a potent stimulus for endothelial cell differentiation.
One of the major conclusions of this study is that caveolin-1
is down-regulated by angiogenic growth factors in subconfluent
endothelial cells (Fig. 1); however, these growth factors do not
down-regulate caveolin-1 expression if these endothelial cells
are confluent (data not shown). Thus, the effects of angiogenic
growth factors on caveolin-1 expression are cell density-de-
pendent. In contrast, recombinant expression of caveolin-1 in
confluent endothelial cells stimulates endothelial cell differen-
tiation and tubule formation (Figs. 4 and 5); this effect can be
mimicked by cell-permeable caveolin-derived peptides (Figs. 7,
8, and 9). These observations are consistent with the finding
that caveolin-1 protein levels are normally up-regulated during
endothelial cell differentiation and tubule formation (Fig. 2).
Conversely, antisense-mediated ablation of caveolin-1 expres-
sion during endothelial cell differentiation prevents tubule for-
mation (Fig. 6). Thus, caveolin-1 is down-regulated during en-
dothelial cell proliferation and up-regulated during endothelial
cell differentiation/tubule formation, and caveolin-1 expression
facilitates endothelial cell differentiation. As such, caveolin-1
expression serves different roles during the different phases of
angiogenesis: (i) the initial proliferative phase versus (ii) the
terminal differentiation phase. As caveolin-1 is a known inhib-
itor of cell proliferation and a widely accepted marker of differ-
entiation, it would be predicted that caveolin-1 levels would be
down-regulated during endothelial cell proliferation and up-
regulated during endothelial differentiation, exactly as we ob-
served here. Furthermore, our current findings are the first
demonstration that caveolin-1 expression can stimulate a dif-
ferentiation process.
Proliferation and differentiation are hallmarks of the devel-
opmental process; however, what lies at the interface between
these two opposing processes remains to be elucidated. Several
features of caveolin-1 make it an attractive candidate to act as
a “toggle switch” between proliferation and differentiation in
numerous cell types. In NIH 3T3 cells, caveolin-1 expression
levels are down-regulated when cells are rapidly dividing and
are dramatically up-regulated at confluency (30), suggesting
that up-regulation of caveolin-1 expression may be important
to mediate normal contact inhibition. In addition, caveolin-1
expression has been demonstrated to negatively regulate the
activated state of the p42/44 MAPK cascade in numerous cell
types (30). Further evidence has also shown that overexpres-
sion of caveolin-1 blocks the oncogenic transformation of NIH
3T3 cells and inhibits the proliferation of human breast cancer
cells (27, 29–32).
Indeed, caveolins are most abundantly expressed in termi-
nally differentiated cells such as endothelial cells, adipocytes,
and myocytes and are dramatically up-regulated during adipo-
genesis and myotube formation (21, 23). For example, C2C12
muscle cells dramatically induce caveolin-3 mRNA and protein
expression during differentiation, coincident with myotube for-
mation. Interestingly, using an antisense approach, our group
has demonstrated that C2C12 cells that fail to express caveo-
FIG. 9. The caveolin-1 scaffolding domain is sufficient to en-
hance endothelial tubule formation. HMEC-1 cells were seeded at
a density of 3  104 cells/well in Matrigel-precoated 96-well plates. One
hour after plating, the cells were treated with a panel of penetratin-
derived peptides (illustrated in Fig. 7) at a concentration of 5 M for a
period of 20 h. A, bright-field views were taken after 20 h of incubation
on Matrigel. Panel a, penetratin (Pen) alone; panel b, Pen-C1-SD; panel
c, B-Pen alone; panel d, B-Pen-C1-SD; panel e, B-3Pro alone; panel f,
B-3Pro-C1-SD. B, capillary-like tubular structures were scored by
counting the number of tubules in each well. Data are the means  S.D.
from three independent experiments, each performed in duplicate.
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lin-3 are unable to undergo myoblast fusion and therefore
cannot form myotubes (31). In addition, we found that three
human rhabdomyosarcoma cell lines that do not express caveo-
lin-3 fail to undergo myoblast fusion.
Therefore, one hypothesis is that caveolin may serve as a
“differentiation sensor” that monitors and responds to changes
in the relative balance of positive and negative factors to “tell”
a target cell whether to remain quiescent or to become prolif-
erative. It is clear that this hypothesis, which has been sup-
ported by adipocytes and muscle cells, is now supported by
endothelial cells as well. In addition, Griffoni et al. (44) showed
that antisense caveolin-1 oligodeoxynucleotides partially in-
hibit blood vessel development in chick embryo chorioallantoic
membranes. However, a lack of critical controls leaves the
conclusions of this study open to question. To investigate
whether caveolin-1 behaves similarly in endothelial cells as
compared with other cell systems, we asked three separate
questions: 1) do angiogenic signals given under growth condi-
tions (low confluency) down-regulate caveolin-1 expression; 2)
is caveolin-1 up-regulated during endothelial tubule formation;
and 3) is caveolin-1 expression necessary for tubule formation
(confluent conditions)? To answer the latter question, we em-
ployed the Matrigel three-dimensional gel system.
It is now well accepted that the Matrigel system is one of the
reliable models to assess angiogenesis in vitro (45, 46). Short-
term culture on Matrigel does not involve cell proliferation and
migration (47, 48). Hence, in this study, we employed the
Matrigel assay system to investigate the potential role of caveo-
lin in endothelial cell differentiation. The Matrigel matrix is a
mixture of mouse basement membrane extracted from the En-
gelbreth-Holm-Swarm mouse sarcoma, a tumor rich in extra-
cellular matrix proteins (47, 49, 50). It is composed of laminin,
collagen type IV, entactin/nidogen, and heparan sulfate proteo-
glycan. It also contains growth factors, matrix metalloprotein-
ases, and other components. Thus, the Matrigel matrix closely
mimics the physical properties and functional characteristics of
basement membranes in vivo (51).
We seeded endothelial cells at super-confluency and incu-
bated them on Matrigel for a short period of time (not 24 h) to
focus primarily on the effect of caveolin-1 on endothelial cell
differentiation. Our current results clearly demonstrate that
up-regulation of caveolin-1 expression dramatically accelerates
endothelial cell differentiation (i.e. tubule formation appeared
after only 6 h of incubation in caveolin-1-overexpressing cells
versus 12 h in control cells) and leads to a dramatic increase in
the number of capillary-like tubular structures. These obser-
vations are further supported by our use of an antisense ad-
enoviral approach that shows that down-regulation of caveo-
lin-1 expression almost completely prevents tubule formation
(i.e. it reduced the formation of tubular structures by 10-fold).
Consistent with the unique function of the caveolin-1 scaffold-
ing domain and its interaction with key signaling molecules, we
show that delivery of the caveolin-1 scaffolding domain into the
cytoplasm of living endothelial cells is sufficient to enhance
capillary-like tubule formation. Given the observations that (i)
caveolin-1 functions as an endogenous inhibitor of the p42/44
MAPK signaling cascade and (ii) up-regulation of caveolins is
crucial for the differentiation of muscle cells as well as epithe-
lial cells (31, 32, 52), our current results are consistent with the
idea that caveolin-1 expression also plays a critical role in the
regulation of endothelial cell differentiation and angiogenesis.
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